USANA Health Sciences (NYSE:USNA) Director Sells $43,928.50 in Stock

USANA Health Sciences, Inc. (NYSE:USNA) Director John Turman Fleming sold 2,450 shares of the firm’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $17.93, for a total value of $43,928.50. Following the completion of the transaction, the director directly owned 4,230 shares in the company, valued at approximately $75,843.90. This represents a 36.68% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.

USANA Health Sciences Stock Performance

Shares of USANA Health Sciences stock opened at $17.47 on Thursday. USANA Health Sciences, Inc. has a one year low of $16.60 and a one year high of $38.32. The stock’s fifty day moving average is $18.36 and its 200 day moving average is $19.44. The stock has a market cap of $322.42 million, a P/E ratio of 37.16, a P/E/G ratio of 0.71 and a beta of 0.76.

USANA Health Sciences (NYSE:USNA) last announced its earnings results on Tuesday, May 5th. The company reported $0.61 EPS for the quarter, topping analysts’ consensus estimates of $0.44 by $0.17. The company had revenue of $250.22 million for the quarter, compared to analysts’ expectations of $240.99 million. USANA Health Sciences had a return on equity of 6.21% and a net margin of 0.96%.USANA Health Sciences has set its FY 2026 guidance at 1.950-2.290 EPS. Analysts predict that USANA Health Sciences, Inc. will post 2.12 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have commented on USNA. Wall Street Zen cut USANA Health Sciences from a “buy” rating to a “hold” rating in a report on Saturday, May 2nd. Zacks Research cut USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a report on Wednesday, April 22nd. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of USANA Health Sciences in a report on Friday, March 27th. One research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Reduce”.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. National Bank of Canada FI grew its position in shares of USANA Health Sciences by 166.6% during the third quarter. National Bank of Canada FI now owns 1,922 shares of the company’s stock valued at $53,000 after purchasing an additional 1,201 shares in the last quarter. State of Wyoming purchased a new position in shares of USANA Health Sciences during the first quarter valued at about $57,000. Tower Research Capital LLC TRC grew its position in shares of USANA Health Sciences by 382.5% during the second quarter. Tower Research Capital LLC TRC now owns 2,398 shares of the company’s stock valued at $73,000 after purchasing an additional 1,901 shares in the last quarter. Parallel Advisors LLC grew its position in shares of USANA Health Sciences by 1,354.3% during the fourth quarter. Parallel Advisors LLC now owns 3,854 shares of the company’s stock valued at $76,000 after purchasing an additional 3,589 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of USANA Health Sciences by 52.9% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,834 shares of the company’s stock valued at $106,000 after purchasing an additional 1,327 shares in the last quarter. Hedge funds and other institutional investors own 54.25% of the company’s stock.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc is a Utah‐based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company’s portfolio includes vitamins, minerals, dietary supplements, weight‐management products and skin‐care formulations. USANA’s products are formulated in its own laboratories to meet pharmaceutical‐grade standards, and the company has invested heavily in research and development and quality control to support its offerings.

Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.